Physician

Chetan Vedvyas, M.D.

According to 2025 Medicare claims, Chetan Vedvyas, M.D. (NPI: 1427342203) practices dermatology in the Punta Gorda, FL market, with the plurality of this provider's patient population coming from Charlotte, FL. This provider's primary affiliated billing organization is LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC (NPI: 1528097284; TIN: 593549147) and primary practice location at 33950-3833. Vedvyas is affiliated with the Rancho Health Management, LLC (ACO ID: D0015), participating under the REACH model.

Vedvyas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 673 traditional Medicare patients, billed 3,424 HCPCS/CPT codes, and received $1,278,723 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 2,297 prescription claims across 849 beneficiaries totaling $17,850 in drug costs, led by Mupirocin (Mupirocin). Open Payments data shows 11 records totaling $270. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $224,415 and ending at $1,278,723. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $155,411 and ending at $17,850. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	179	859	$224,415
2017	860	4,237	$1,290,786
2018	286	1,698	$267,449
2019	693	5,295	$675,132
2020	883	6,447	$802,108
2021	873	6,220	$770,049
2022	753	3,739	$640,652
2023	634	3,329	$700,826
2024	673	3,424	$1,278,723

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	40	$155,411
2016	74	117	$3,298
2017	598	1,279	$16,863
2018	193	424	$5,509
2019	484	1,312	$196,579
2020	639	1,537	$65,302
2021	736	1,742	$61,699
2022	759	1,854	$38,699
2023	843	2,310	$23,416
2024	849	2,297	$17,850

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17311	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks	361	477	$466
17312	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks	166	247	$316
13132	Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm	208	253	$183
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	232	307	$63
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	153	177	$41

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Mupirocin	Mupirocin	1,012	16,529	$6,826
Minocycline Hcl	Minocycline Hcl	814	5,703	$4,952
Gentamicin Sulfate	Gentamicin Sulfate	60	1,306	$2,171
Fluorouracil	Fluorouracil	25	832	$1,624
Acetaminophen-Codeine	Acetaminophen With Codeine	127	414	$383

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$270	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chetan Vedvyas, M.D.?

Tedicare shows public-source Medicare data for Chetan Vedvyas, M.D. (NPI 1427342203), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chetan Vedvyas, M.D. have ACO affiliation data?

Chetan Vedvyas, M.D. is shown with ACO affiliation data for Rancho Health Management, LLC (REACH, ACO ID D0015).

What billing organization is linked to Chetan Vedvyas, M.D.?

Chetan Vedvyas, M.D. is linked to LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC (billing NPI 1528097284) in the available physician profile data.

Does Chetan Vedvyas, M.D. have Open Payments data?

Chetan Vedvyas, M.D. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.